Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab.
Marchesoni
A
A
Arreghini
M
M
Panni
B
B
Battafarano
N
N
Uziel
L
L
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D007555:Isoxazoles / Q000009:adverse effects; D000077339:Leflunomide; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D010198:Pancytopenia / Q000139:chemically induced*; D013256:Steroids
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007555:Isoxazoles; D013256:Steroids; D000069285:Infliximab; D000077339:Leflunomide; D008727:Methotrexate